A detailed history of Achmea Investment Management B.V. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Achmea Investment Management B.V. holds 5,742 shares of ALNY stock, worth $1.35 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
5,742
Previous 4,014 43.05%
Holding current value
$1.35 Million
Previous $975,000 61.95%
% of portfolio
0.03%
Previous 0.02%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$233.81 - $287.01 $404,023 - $495,953
1,728 Added 43.05%
5,742 $1.58 Million
Q4 2023

Feb 12, 2024

SELL
$151.41 - $196.57 $743,574 - $965,355
-4,911 Reduced 55.03%
4,014 $769,000
Q3 2023

Nov 06, 2023

SELL
$170.77 - $211.65 $31,421 - $38,943
-184 Reduced 2.02%
8,925 $1.58 Million
Q2 2023

Jul 24, 2023

BUY
$185.01 - $212.05 $314,146 - $360,060
1,698 Added 22.91%
9,109 $1.73 Million
Q1 2023

May 04, 2023

BUY
$182.66 - $235.53 $533,184 - $687,512
2,919 Added 64.98%
7,411 $1.48 Million
Q4 2022

Feb 09, 2023

BUY
$185.53 - $241.31 $799,263 - $1.04 Million
4,308 Added 2341.3%
4,492 $1 Million
Q3 2021

Nov 12, 2021

BUY
$169.75 - $207.73 $31,234 - $38,222
184 New
184 $35,000
Q3 2020

Nov 02, 2020

SELL
$121.19 - $165.49 $1.51 Million - $2.06 Million
-12,459 Closed
0 $0
Q2 2020

Aug 12, 2020

SELL
$104.21 - $156.44 $662,775 - $994,958
-6,360 Reduced 33.8%
12,459 $1.85 Million
Q1 2020

May 13, 2020

BUY
$93.12 - $133.99 $1.06 Million - $1.53 Million
11,425 Added 154.52%
18,819 $2.05 Million
Q4 2017

Feb 12, 2018

BUY
$114.49 - $139.98 $846,539 - $1.04 Million
7,394
7,394 $939,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Achmea Investment Management B.V. Portfolio

Follow Achmea Investment Management B.V. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Achmea Investment Management B.V., based on Form 13F filings with the SEC.

News

Stay updated on Achmea Investment Management B.V. with notifications on news.